Last $2.18 USD
Change Today -0.04 / -1.80%
Volume 50.9K
ERB On Other Exchanges
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

erba diagnostics inc (ERB) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/14 - $4.13
52 Week Low
07/29/13 - $0.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ERBA DIAGNOSTICS INC (ERB)

Related News

No related news articles were found.

erba diagnostics inc (ERB) Related Businessweek News

No Related Businessweek News Found

erba diagnostics inc (ERB) Details

ERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures, and markets diagnostic test kits or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing. It manufactures scientific and laboratory instruments, such as Mago 4, Mago 4S, and Mago Plus systems, which perform tests in an automated mode; sells other diagnostic products in Italy; and develops, manufactures, and markets diagnostic equipment, as well as raw materials, such as antigens that are used in the production of diagnostic kits. The company also develops, manufactures, and markets autoimmune reagents and research products for use by research laboratories and commercial diagnostic manufacturers. In addition, the company provides instruments for blood cell counting and blood analysis; supplies reagents and other consumable materials; sells diabetic testing products, including the DS5 instrument, dispenser, and associated reagent kits, which measure long-term glucose control in diabetic patients; and offers equipment for use in the field of human and veterinary hematology. Further, it manufactures and sells liquid stable, diagnostics chemistry reagents used for in vitro diagnostics testing. The company markets its products through its sales force to hospitals, reference laboratories, clinical laboratories, and research laboratories, as well as to other commercial companies that manufacture diagnostic products in the United States; and through sales representatives and independent agents in Italy, as well as through independent distributors internationally. ERBA Diagnostics, Inc. was founded in 1980 and is headquartered in Miami Lakes, Florida. ERBA Diagnostics, Inc. is a subsidiary of ERBA Diagnostics Mannheim GmbH.

135 Employees
Last Reported Date: 04/14/14
Founded in 1980

erba diagnostics inc (ERB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $150.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $47.4K
Compensation as of Fiscal Year 2013.

erba diagnostics inc (ERB) Key Developments

ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing

ERBA Diagnostics, Inc. appointed William Creech as Vice President Sales and Marketing. Creech has over 20 years of successful experience in the diagnostics industry. His last assignment was with Vermillion Inc., a diagnostics company, as Vice President Sales and Marketing, leading the commercialization of a novel test for ovarian cancer. Prior to that, Mr. Creech worked in various capacities of increasing responsibilities with Abbott Laboratories Diagnostics Division, Siemens Healthcare and Thermo Fisher Scientific, where he was VP Sales and Marketing, Capitol Vial subsidiary.

ERBA Diagnostics, Inc. Announces Management Changes

On May 20, 2014, Sanjiv Suri, the Interim Chief Executive Officer of ERBA Diagnostics, Inc., delivered notice to the company of his intention to resign effective as of June 1, 2014. Effective as of June 1, 2014, Mohan Gopalkrishnan will become the Chief Executive Officer of the company. Mr. Gopalkrishnan has served as Vice President - Operations of the company since October 2012. Effective as of June 1, 2014, Prakash Patel will become the Controller of the company. Mr. Patel has served as Assistant Controller of the company since June 3, 2013, and as the Principal Financial Officer and Principal Accounting Officer of the company since June 30, 2013.

ERBA Diagnostics, Inc. Receives 510(K) Clearance for the XL200 Clinical Chemistry Analyzer

ERBA Diagnostics, Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) on the 510(k) premarket submission that ERBA Diagnostics had filed for its new clinical chemistry analyzer -- the XL 200. The XL-200 is a random access, clinical chemistry analyzer that can perform up to 400 tests per hour. Clinical chemistry analysis is one of the most widely and routinely performed diagnostics procedures in all clinical diagnostics laboratories.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERB:US $2.18 USD -0.04

ERB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $39.24 USD +0.65
Bio-Rad Laboratories Inc $118.61 USD +0.11
DiaSorin SpA €30.28 EUR -0.22
Meridian Bioscience Inc $20.84 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ERB Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 5.5x
Price/Cash Flow 89.6x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERBA DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at